I think it is reasonable to explore non-psychedelic analogues as early rodent research is promising. It shouldn’t be viewed as heresy against psychedelic medicine. It is just a different treatment model. We need more tools than fewer. It would be a different model likely requiring regular (e.g., weekly) administration, rather than taking the substance 1 or a few times and seeing large benefit a year later or more as we see will full high dose psychedelic therapy.
I think it is reasonable to explore non-psychedelic analogues as early rodent research is promising. It shouldn’t be viewed as heresy against psychedelic medicine. It is just a different treatment model. We need more tools than fewer. It would be a different model likely requiring regular (e.g., weekly) administration, rather than taking the substance 1 or a few times and seeing large benefit a year later or more as we see will full high dose psychedelic therapy.